## 1 Associations of the Triglyceride and Glucose Index with Hypertension Stages, Phenotypes,

## 2 and Progressions among Middle-aged and Older Chinese

- 3
- Shiyi Shan<sup>1,#</sup>, Shuting Li<sup>1,#</sup>, Keyao Lu<sup>1</sup>, Jin Cao<sup>1</sup>, Weidi Sun<sup>1</sup>, Jiali Zhou<sup>1</sup>, Ziyang Ren<sup>1,2,3</sup>, Siyu
  Zhu<sup>1</sup>, Leying Hou<sup>1</sup>, Dingwan Chen<sup>4</sup>\*, Peige Song<sup>1</sup>\*
- 6 <sup>1</sup> School of Public Health and Women's Hospital, Zhejiang University School of Medicine,
- 7 Hangzhou, Zhejiang, China.
- 8 <sup>2</sup> Institute of Reproductive and Child Health / Key Laboratory of Reproductive Health, National
- 9 Health Commission of the People's Republic of China, Peking University, Beijing, China.
- <sup>3</sup> Department of Epidemiology and Biostatistics, School of Public Health, Peking University,
- 11 Beijing, China.
- <sup>4</sup> School of Public Health, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- 13
- <sup>#</sup> The authors contributed equally to the paper.

## 15 \* Corresponding Author:

- 16 Dingwan Chen,
- 17 School of Public Health, Hangzhou Medical College, Hangzhou, Zhejiang, China
- 18 Email: chendw@hmc.edu.cn
- 19 Peige Song, PhD,
- 20 School of Public Health and Women's Hospital, Zhejiang University School of Medicine,
- 21 Hangzhou, Zhejiang, China
- 22 Email: peigesong@zju.edu.cn
- 23

## 24 Abstract

#### 25 Background

26 The triglyceride and glucose (TyG) index has been proposed as a surrogate indicator of insulin

- 27 resistance. By far, the associations of the TyG index with hypertension stages, phenotypes, and
- 28 progressions remain unclear.
- 29 Methods

30 The data originated from two waves (2011 and 2015) of the China Health and Retirement 31 Longitudinal Study (CHARLS). Participants with systolic blood pressure  $\geq$  140 mmHg and/or 32 diastolic blood pressure  $\geq$  90 mmHg and/or using antihypertensive medications were considered 33 hypertensive. After excluding those under antihypertensive medications, hypertension stages were 34 classified as stage 1 and stage 2, and phenotypes were classified as isolated systolic hypertension 35 (ISH), isolated diastolic hypertension (IDH), and systolic diastolic hypertension (SDH). 36 Multinomial logistic regression was used to investigate the associations of the TyG index with 37 hypertension stages and phenotypes, together with their progressions from 2011 to 2015.

#### 38 Results

At baseline in CHARLS 2011, a total of 8,209 participants were recruited, among whom 3,169 (38.6%) were hypertension. Compared with individuals with the lowest quartile (Q1) of TyG index, those with the highest quartile (Q4) were significantly associated with increased risks of stage 1 hypertension (odds ratio [OR] 1.71, 95% confidence interval [CI] 1.38-2.13), stage 2 hypertension (1.74, 1.27-2.38), ISH (1.66, 1.31-2.11), IDH (2.52, 1.26-5.05), and SDH (1.65, 1.23-2.23). Similar results were found when the TyG index was used as a continuous variable. From 2011 to 2015, a higher baseline TyG index was revealed to be significantly associated with

- 46 the progressions from normotension to stage 1 (for Q4 vs Q1: 1.45, 1.05-2.00; for per-unit: 1.39,
- 47 1.16-1.65), normotension to ISH (for per-unit: 1.28, 1.04-1.56), and normotension to IDH (for Q4
- 48 vs Q1: 3.46, 1.42-8.44; for per-unit: 1.94, 1.27-2.97).
- 49 Conclusions
- 50 The TyG index was significantly associated with different hypertension stages, phenotypes and
- 51 their progressions. Our findings highlight the importance of the TyG index as a potential surrogate
- 52 indicator for early hypertension screening and management.
- 53 *Keywords:* triglyceride and glucose; hypertension; status; stages; phenotypes; Chinese

54

#### 55 Introduction

56 Hypertension can lead to myocardial infarction, renal failure, and even death if not treated appropriately<sup>1,2</sup>. According to the World Health Organization report, hypertensive heart disease is 57 one of the top 10 causes of death in upper-middle-income countries in 2019<sup>3</sup>. It is estimated that 58 1.28 billion adults aged 30-79 years are affected by hypertension in 2021<sup>4</sup>. In China, hypertension 59 60 has evolved into a serious public health concern, as its burden grows in tandem with increased urbanization, population ageing, and exposure to unhealthy lifestyles<sup>5-10</sup>. A review from Yin et al. 61 reported that the prevalence of hypertension ranged from 18.0% to 44.7% in China<sup>11</sup>. According to 62 63 the Chinese Guidelines for Prevention and Treatment of Hypertension (2018 Edition), 64 hypertension statuses can be divided into hypertension and normotension, hypertension stages are 65 classified as stage 1, stage 2, and stage 3 and hypertension phenotypes are classified as isolated 66 systolic hypertension (ISH), isolated diastolic hypertension (IDH), and systolic diastolic hypertension (SDH)<sup>12</sup>. Besides, as the course of hypertension progresses, changes in hypertension 67 68 statues or stages or phenotypes will occur, namely hypertension progressions. Investigating the 69 progressions of hypertension can help to conduct dynamic management and treatment of 70 hypertension more accurately.

71 The triglyceride and glucose (TyG) index, calculated as ln(fasting triglycerides [TG] [mg/72  $dl \propto fasting plasma glucose[FPG][mg/dl]/2)$ , has attracted increasing interest due to its excellent sensitivity (79%) and specificity (86%) for diagnosing insulin resistance (IR)<sup>13-15</sup>. 73 74 Previous studies mainly focused on the association between the TyG index and the risk of 75 hypertension in adults, and suggested that the TyG index was a superior indicator for hypertension than independent lipid or glycemic markers<sup>16-19</sup>. To the best of our knowledge, limited studies 76 77 have explored the associations of the TyG index with various hypertension stages and phenotypes, 78 let alone their progressions.

To fill the research gap, this study aims to evaluate the associations of the TyG index with hypertension stages and phenotypes. And we also investigate whether the TyG index is associated with the progressions of hypertension stages and phenotypes.

82

83 Methods

#### 84 Study population

85 This study used data from the China Health and Retirement Longitudinal Study (CHARLS), a nationwide longitudinal survey of people aged 45 years or above<sup>20</sup>. A stratified four-stage 86 87 probability sampling strategy was adopted to recruit participants from 150 counties and urban 88 districts across 28 provinces in China. The baseline survey was conducted in 2011. Respondents 89 were then followed up with a face-to-face computer-assisted personal interview every two years (2013, 2015, and 2018, respectively). Detailed study procedures can be found elsewhere<sup>20</sup>. 90 91 CHARLS was approved by the Behavioral and Social Research division of the National Institute 92 on Aging of the National Institute of Health, the Natural Science Foundation of China, the World 93 Bank, and Peking University.

#### 94 Measurement of blood-based biomarkers

95 Blood sample collection was done once every two follow-up periods (2011 and 2015). Biomarkers 96 were measured using overnight fasting blood samples, which were promptly transported to the 97 local laboratory and stored at  $4\Box$ . The blood samples were centrifugated and stored at  $-20\Box$  before 98 being transported to the China Center for Disease Prevention and Control (CDC) in Beijing and 99 frozen at  $-70\Box$  before analysis<sup>20</sup>. Routine blood tests were performed at township hospitals or the 100 local CDC. FPG was measured using the enzymatic method. TG, high-density lipoprotein 101 cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured using the enzymatic colour metric method<sup>21</sup>. C-reactive protein (CRP) was measured using the 102 103 colourimetric enzyme-linked immunosorbent assay<sup>22</sup>.

104 The TyG index was calculated as  $ln[TG (mg/dl) \times FPG (mg/dl)/2)]^{13}$ .

#### 105 Definition of hypertension stages, phenotypes and progressions

Blood pressure (BP) was measured three times in a sitting position at a 45-second interval using an electronic monitor (Omron model HEM-7200). The average of the three measurements was calculated to the nearest 0.1 mmHg for analysis. Hypertension statuses were divided into hypertension and normotension. Hypertension was defined as mean systolic blood pressure (SBP)  $\geq 140$  mmHg and/or mean diastolic blood pressure (DBP)  $\geq 90$  mmHg and/or using antihypertensive medications<sup>12,20</sup>. Normotension was defined as SBP < 140 mmHg and DBP < 90 mmHg. After excluding those with antihypertensive medications, hypertension stages were further

113	classified as stage 1 hypertension (SBP $\ge$ 140 mmHg and < 159 mmHg and/or DBP $\ge$ 90
114	mmHg and < 99 mmHg), stage 2 hypertension (SBP $\geq$ 160 mmHg and < 179 mmHg and/or DBP
115	$\geq$ 100 mmHg and < 109 mmHg), and stage 3 hypertension (SBP $\geq$ 180 mmHg and/or DBP $\geq$
116	110 mmHg). Given the sample size constraints, we combined stage 2 and stage 3 hypertension
117	into stage 2 hypertension. Hypertension phenotypes were also classified as ISH (SBP $\ge$ 140
118	mmHg and DBP < 90 mmHg), IDH (SBP < 140 mmHg and DBP ≥ 90 mmHg), and SDH (SBP
119	$\geq$ 140 mmHg and DBP $\geq$ 90 mmHg). More details are shown in <b>Table S1</b> . The progressions of
120	hypertension statuses were classified as maintained normotension, normotension to hypertension,
121	and maintained hypertension. The progressions of hypertension stages were classified as
122	maintained normotension, normotension to stage 1, normotension to stage 2, maintained stage 1,
123	stage 1 to stage 2, and maintained stage 2. The progressions of hypertension phenotypes were
124	classified as maintained normotension, normotension to ISH, normotension to IDH, normotension
125	to SDH, maintained ISH, ISH to SDH, and maintained SDH.

#### 126 **Definition of covariates**

127 Anthropometric measurements, including height, weight, and waist circumstance (WC), were 128 made at every 2-year follow-up. Information on age, sex, residence, education, economic status, 129 tobacco use, and alcohol consumption were collected through questionnaires. The residence was 130 classified as urban and rural according to the location of the participants. Education was divided 131 into illiterate, primary school and below, and junior high school or above. Economic status was 132 evaluated by the natural logarithm of per capita expenditures (ln[PCE])<sup>23</sup>. The bottom, middle, and 133 top tertile of ln(PCE) indicated poor, middle, and rich economic status, respectively. Tobacco use 134 was categorized as never smoking and ever smoking (including current smoking). Likewise, 135 alcohol consumption was classified as never drinking and ever drinking (including current 136 drinking). Body mass index (BMI) was calculated as (weight  $[kg] / [height [m]]^2$ ). The categories of general obesity included normal (BMI<24 kg/m<sup>2</sup>), overweight (BMI≥24 kg/m<sup>2</sup> and 137 BMI<28 kg/m<sup>2</sup>), and obesity (BMI $\ge$ 28 kg/m<sup>2</sup>)<sup>24</sup>. 138

# 139 Statistical analysis

140 Characteristics of participants at baseline (CHARLS 2011) were described in the form of the 141 median with interquartile range (IQR) for continuous variables with skewed distribution, and 142 number with percent (%) for categorical variables. The basic characteristics of participants 143 between the included participants and excluded participants, between normotension and 144 hypertension, among different hypertension stages, hypertension phenotypes, and hypertension 145 progressions were compared using Wilcoxon rank-sum test for continuous variables and the 146 Chi-square test for categorical variables.

The included participants were divided into four groups based on their TyG index levels (quartile
1, quartile 2, quartile 3 and quartile 4). In the data analysis, the TyG index was considered as a
continuous (per-unit) variable and converted to a categorical (quartiles) variable.

For the cross-sectional analysis in CHARLS 2011, we used multinomial logistic regression to investigate the associations of the TyG index with hypertension statuses, stages, and phenotypes, with normotension as reference. The model was adjusted for age, sex, residence, education, economic status, tobacco use, alcohol consumption, general obesity, WC, LDL-C, HDL-C, and CRP. Meanwhile, considering the sex-TyG index interaction, we conducted sex-stratified multinomial logistic regression as well<sup>25</sup>.

156 For the longitudinal analysis using CHARLS 2011 and 2015, we excluded those who had taken 157 antihypertensive medications to ensure proper classification of hypertension stages and 158 phenotypes. Participants interviewed in both waves with complete data on SBP and DBP were 159 included to further investigate the associations between the TyG index and hypertension 160 progressions. Those who had non-attenuated hypertension progression patterns including 161 maintained normotension, normotension to hypertension, and maintained hypertension based on 162 their hypertension statuses from 2011 to 2015 were included. Subsequently, we selected 163 participants who had non-attenuated hypertension stages (i.e. maintained normotension, 164 normotension to stage 1, normotension to stage 2, maintained stage 1, stage 1 to stage 2, and 165 maintained stage 2) and phenotypes (i.e. maintained normotension, normotension to ISH, 166 normotension to IDH, normotension to SDH, maintained ISH, ISH to SDH, and maintained SDH) 167 to explore whether the TyG index was associated with hypertension stages and phenotypes

- 168 progressions, respectively. All of these analyses were conducted using sex-stratified multinomial
- 169 logistic regression with maintained normotension as reference.
- 170 This study was done following the Strengthening the Reporting of Observational Studies in
- 171 Epidemiology (STROBE) guidelines<sup>26</sup>. SAS statistical software (version 9.4; SAS Institute Inc.,
- 172 Cary, NC, USA) was used. All analyses were two-sided, and statistical significance was defined as

173 a *P* value <0.05.

174

175 Results

#### 176 Selection of study participants

177 A total of 17,708 participants were recruited at baseline in CHARLS 2011. After excluding those 178 under the age of 45 (n=289) or with incomplete data on sex, education, economic status, tobacco 179 use, SBP, DBP, weight, height, and WC (n=6,018), who had incomplete data on TG, FPG, HDL-C, 180 and LDL-C (n=3,192), finally 8,209 participants were included in analyses (Figure 1). 181 Characteristic comparisons between the included (n=8,209) and excluded (n=9,499) participants 182 were shown in Table S2. Table S3 showed that of the 8,209 individuals included in CHARLS 183 2011, 5,040 (61.4%) had normotension, and 3,169 (38.6%) had hypertension. Significant 184 differences in age, residence, education, economic status, alcohol consumption, general obesity, 185 WC, LDL-C, HDL-C, CRP, and the TyG index between different hypertension statuses were 186 observed (all P values <0.05).

## 187 Cross-sectional analyses

For the cross-sectional analysis in CHARLS 2011, we found that when compared with the bottom quartile of baseline TyG index, a higher quartile of TyG index was significantly associated with hypertension (odds ratio [OR] 1.17, 95% confidence interval [CI] 1.01-1.35 for quartile 2; OR 1.48, 95% CI 1.28-1.72 for quartile 3; OR 1.90, 95% CI 1.63-2.23 for quartile 4). Similar results were also found when the TyG index was used as a continuous variable and in the sex-stratified analyses (**Table S4**).

After excluding participants with antihypertensive medications in 2011 (n=1,625), baseline
 characteristics of the remaining 6,584 participants by hypertension stages and phenotypes were

196 shown in **Table S5** and **Table S6**, respectively. We also found that compared with people with the 197 lowest quartile of baseline exposure, those with a higher TyG index had an increased risk of stage 198 1 hypertension (OR 1.26, 95% CI 1.02-1.55 for quartile 3; OR 1.71, 95% CI 1.38-2.13 for quartile 199 4) and stage 2 hypertension (OR 1.52, 95% CI 1.13-2.04 for quartile 3; OR 1.74, 95% CI 200 1.27-2.38 for quartile 4). Furthermore, the TyG index was also positively associated with ISH (OR 201 1.35, 95% CI 1.08-1.68 for quartile 3; OR 1.66, 95% CI 1.31-2.11 for quartile 4), IDH (OR 2.04, 202 95% CI 1.03-4.04 for quartile 3; OR 2.52, 95% CI 1.26-5.05 for quartile 4), and SDH (OR 1.65, 203 95% CI 1.23-2.23 for quartile 4) (Table 1). Similarly, a higher TyG index (per-unit) was 204 significantly associated with the development of stage 1 hypertension (OR 1.43, 95% CI 205 1.27-1.61), stage 2 hypertension (OR 1.42, 95% CI 1.20-1.67), ISH (OR 1.41, 95% CI 1.24-1.61), 206 IDH (OR 1.78, 95% CI 1.30-2.45), SDH (OR 1.35, 95% CI 1.15-1.58). However, neither as a 207 continuous variable nor as a categorical variable of the TyG index, there was no evidence of a 208 significant association between the TyG index and stage 2 hypertension in males.

## 209 Longitudinal analyses

210 In the longitudinal study using CHARLS 2011 and 2015, participants with incomplete data on 211 SBP and DBP (n=1,887) or unrelated hypertension progressions (n=893) were further excluded, 212 leaving 5,429 participants for longitudinal analyses. During the 4-year follow-up, 796 individuals 213 (14.7%) developed hypertension (Table S7). Participants who were in the highest quartile TyG 214 index were more likely to have the progression of normotension to hypertension (normotension to 215 hypertension vs maintained normotension: OR 1.48, 95% CI 1.14-1.92) and maintained 216 hypertension (maintained hypertension vs maintained normotension: OR 2.16, 95% CI 1.74-2.69), 217 compared with those in the lowest quartile TyG index, as shown in Table S8. Associations of the 218 per-unit TyG index with the progression of normotension to hypertension (OR 1.34, 95% CI 219 1.16-1.54) and maintained hypertension (OR 1.59, 95% CI 1.41-1.79) were also found when 220 compared with maintained normotension. However, in females, there was no evidence of 221 significant associations between the TyG index (per-unit) and normotension to hypertension (OR 222 1.18, 95% CI 0.96-1.45), compared with maintained normotension (Table S8).

Furthermore, 4,144 and 4,126 participants were enrolled separately to explore whether the TyG index was associated with the progressions of hypertension stages and phenotypes. Characteristics

of these participants were described in Table S9 and Table S10, respectively. As shown in Table
S11 and Figure 2, individuals with a higher baseline TyG index were more likely to have
progressions of normotension to stage 1 (for highest quartile vs lowest quartile: OR 1.45, 95% CI
1.05-2.00; for per-unit: OR 1.39, 95% CI 1.16-1.65), maintained stage 1 (for highest quartile vs
lowest quartile: OR 1.68, 95% CI 1.10-2.56; for per-unit: OR 1.32, 95% CI 1.05-1.67), and
maintained stage 2 (for highest quartile vs lowest quartile: OR 2.62, 95% CI 1.23-5.62; for per-unit:
OR 2.00, 95% CI 1.37-2.91).

In addition, we also found significant associations of the TyG index with normotension to ISH (per-unit: OR 1.28, 95% CI 1.04-1.56), normotension to IDH (for highest quartile vs lowest quartile: OR 3.46, 95% CI 1.42-8.44; for per-unit: OR 1.94, 95% CI 1.27-2.97), maintained ISH (for highest quartile vs lowest quartile: OR 1.63, 95% CI 1.03-2.57; for per-unit: OR 1.34, 95% CI=1.05-1.70), and maintained SDH (for highest quartile vs lowest quartile: OR 2.66, 95% CI 1.36-5.20; for per-unit: OR 1.71, 95% CI 1.22-2.40) as shown in **Table S12 and Figure 3**.

238

#### 239 Discussion

In this study, we found significant associations between a higher TyG index with increased risks of every hypertension stage and phenotype. Increased TyG index was also associated with the progressions of hypertension status (including normotension to hypertension and maintained hypertension), stages (including normotension to stage 1, maintained stage 1 and maintained stage 2) and phenotypes (including normotension to ISH, normotension to IDH, maintained ISH and maintained SDH).

246 Our results are consistent with previous findings, which discovered that a higher TyG index is associated with higher odds of hypertension<sup>17,18,27-29</sup>. Because of the TyG index's high sensitivity 247 and specificity, it has been proposed as a prominent indicator of IR<sup>14,15</sup>. And the association 248 between IR and hypertension has been verified in some researches<sup>30-32</sup>. So, several potential 249 250 mechanisms via IR may explain our main results. IR may cause hyperinsulinemia and elevate blood pressure by stimulating the sympathetic nervous system and the adrenergic system<sup>33-35</sup>. 251 252 Increased insulin enhances insulin-mediated glucose metabolism in neurons and stimulates the sympathetic centre in the brain stem, resulting in higher BP<sup>36</sup>. What's more, sympathetic 253 254 excitement can generate increased catecholamine levels, which thicken vascular smooth muscle

and lead to hypertension<sup>37</sup>. IR may also promote the release of angiotensin II by activating the renin-angiotensin system (RAS). Angiotensin II can inhibit the phosphatidylinositol 3-kinase pathway while activating the mitogen-activated protein kinase pathway and finally contribute to hypertension<sup>35,38,39</sup>. Meanwhile, elevated angiotensin II promotes adrenal aldosterone secretion and leads to sodium retention, plasma volume expansion, and non-genetic mineralocorticoid receptor mediation, all of which play an important role in hypertension pathogenesis<sup>40,41</sup>.

261 Our study supplemented previous findings and revealed that the TyG index was associated with multiple hypertension stages and phenotypes, as well as their progressions. Kaze et al.<sup>42</sup> found a 262 263 positive association between the development of IR and BP progressions, which aligns with our 264 findings. In particular, we found that a higher TyG index was associated with minor hypertension 265 progressions (i.e. normotension to stage 1, normotension to ISH, and normotension to IDH), 266 implying that the TyG index could be a potential early screening indicator for hypertension. Given 267 our sample limitations, we conducted our study in the general population but not in patients with 268 hypertension, which may pull down the average TyG level and lead to the non-significant 269 association of the TyG index with normotension to stage 2 and normotension to SDH. Therefore, 270 the association of the TyG index with hypertension progressions across a broader range warrants 271 further validation in larger-scale studies. However, in the sex-stratified analysis, we found that a 272 higher TyG index was significantly associated with stage 2 hypertension in females, but not in 273 males. The sex-stratified results may be related to the change in female estrogen levels. Research 274 has shown that endogenous estrogen may play a role in higher insulin sensitivity in females<sup>43</sup>. Our 275 study included females who were older than 45 years, and most of them were postmenopausal. 276 Their dropping estrogen level resulted in a decrease of insulin sensitivity, making them susceptible 277 to IR. Moreover, we found that a higher TyG index was significantly correlated with different 278 progressions of hypertension in males (normotension to stage 1, normotension to ISH, 279 normotension to IDH, maintained SDH), but not in females. Differences in the preferred location of fat storage between men and women may also affect the development of  $IR^{44,45}$ . 280 281 Women are more likely to store fat subcutaneously, while men store more abdominal fat with a higher amount of abdominal visceral fat and ectopic fat<sup>46,47</sup>. Therefore, the level of visceral fat 282 283 storage will be higher in men than in women with the same BMI. Visceral fat is strongly 284 associated with IR, which may lead to sex differences in the progression of hypertension.

## 285 Strengths and limitations

The principal strength of this study is that we are the first to explore the associations of the TyG index with various hypertension stages and phenotypes, as well as their progressions, in a large Chinese general population. Since the TyG index is a recently proposed and high-profile indicator, our findings assist to accelerate the clinical application of the TyG index and facilitate early hypertension screening. Moreover, we used data from the CHARLS, which has broad geographic coverage, rigorous implementation procedures, and nationwide samples to warrant the generalizability of our conclusions.

293 Despite these strengths, several limitations need to be recognized. First, the TyG index was only 294 assessed in 2011, and its changes during follow-up were not taken into account. Second, there 295 were significant characteristic differences between included and excluded participants (**Table S2**), 296 which may lead to selection bias and affect national representation. Third, since all participants 297 were Chinese adults aged 45 and over, our findings cannot be directly extrapolated to younger 298 groups. Fourth, we merged stage 2 and stage 3 hypertension into stage 2 hypertension due to the 299 limited sample size, which may result in misjudging the association between the TyG index and 300 stage 2 hypertension, or the progressions. Moreover, the participants in our study are the general 301 population but not the patients with hypertension, which may pull down the average TyG level and 302 lead to the non-significant association of the TyG index with normotension to stage 2 and 303 normotension to SDH. More high-quality epidemiologic investigations and primary prevention 304 studies are needed to explore the role of TyG index in the progression of hypertension. Finally, 305 even though the model we used was adjusted for multiple covariates, certain possible confounding 306 factors, such as exercise habits and family history of hypertension, were not included.

307 Conclusion

308 In conclusion, our study revealed that a higher TyG index was significantly associated with 309 hypertension stages, phenotypes, and their progressions. Given the rising prevalence of 310 hypertension and diabetes in China, the TyG index may serve as a useful indicator for the early 311 prevention of hypertension.

#### 312 Ethics statement

The study protocol and data collection were approved by the Ethical Review Committee of PekingUniversity. All respondents were informed and consented to the study protocol before data

315 collection.

## 316 Data availability statement

- 317 The dataset presented in this study can be found in online repositories. Requests to access the
- 318 datasets should be directed to http://charls.pku.edu.cn/.

## 319 Conflict of interest

- 320 The authors declare that the research was conducted in the absence of any commercial or financial
- 321 relationships that could be construed as a potential conflict of interest.
- 322 Funding
- 323 This study has no funding.

## 324 Authors' contributions

- 325 PS and DC designed the study. ZR and SS managed and analyzed the data. SS and KL prepared
- 326 the first draft. PS, DC, SS, SL, KL, JC, WS, JZ, SZ and LH critically revised the manuscript. All
- 327 authors were involved in revising the paper and gave final approval of the submitted versions.

# 328 Acknowledgements

All authors thank the China Health and Retirement Longitudinal Study (CHARLS) team forproviding data and instructions for using the dataset.

331

332 Figure 1. Flow chart of study participants

333 Notes: SBP, systolic blood pressure. DBP, diastolic blood pressure. WC, waist circumstance. TG,

- 334 fasting triglycerides. FPG, fasting plasma glucose. LDL-C, low-density lipoprotein cholesterol.
- 335 HDL-C, high-density lipoprotein cholesterol. ISH, isolated systolic hypertension. IDH, isolated
- 336 diastolic hypertension. SDH, systolic diastolic hypertension. Unrelated hypertension progressions:
- 337 hypertension to normotension. Unrelated progressions of hypertension stages: stage 2 to stage 1,
- 338 stage 2 to normotension, stage 1 to normotension. Unrelated progressions of hypertension
- 339 phenotypes: ISH to normotension, ISH to IDH, IDH to normotension, IDH to ISH, SDH to
- 340 normotension, SDH to ISH, SDH to IDH.

- 341 Figure 2. Odds ratios and 95% confidence interval of the progressions of hypertension stages by
- 342 the TyG index
- 343 Figure3. Odds ratios and 95% confidence interval of the progressions of hypertension phenotypes
- 344 by the TyG index
- 345 Notes: ISH, isolated systolic hypertension. IDH, isolated diastolic hypertension. SDH, systolic
- 346 diastolic hypertension.
- 347

348

## 349 Reference

- 350 James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the 1. 351 management of high blood pressure in adults: report from the panel members 352 appointed to the Eighth Joint National Committee (JNC 8). Jama. 353 2014;311(5):507-520.
- Price RS, Kasner SE. Hypertension and hypertensive encephalopathy. *Handbook of clinical neurology*. 2014;119:161-167.
- 356 3. WHO. The top 10 causes of death. December 9, 2020;
- 357 https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
- 358
   4.
   Hypertension.
   25
   August
   2021;
- 359 https://www.who.int/news-room/fact-sheets/detail/hypertension.
- 360 5. Global, regional, and national age-sex specific mortality for 264 causes of death,
- 361 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.
- 362 *Lancet (London, England).* 2017;390(10100):1151-1210.
- 363 6. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings
- 364 from the Global Burden of Disease Study 2010. *Lancet (London, England).*
- 3652013;381(9882):1987-2015.
- 366 7. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality,
- and life expectancy, 1970-2016: a systematic analysis for the Global Burden of
   Disease Study 2016. *Lancet (London, England)*. 2017;390(10100):1084-1150.
- 369 8. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and
- 370 Control: A Systematic Analysis of Population-Based Studies From 90 Countries.

#### Circulation. 2016;134(6):441-450. 371

372	9.	Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: Results From the
373		China Hypertension Survey, 2012-2015. <i>Circulation.</i> 2018;137(22):2344-2356.
374	10.	Pencina M, Pencina K, Lloyd-Jones D, Catapano A, Thanassoulis G, Sniderman AJC.
375		The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of
376		Cardiovascular Disease by Lipid Lowering. <i>Circulation.</i> 2020;142(9):827-837.
377	11.	Yin R, Yin L, Li L, et al. Hypertension in China: burdens, guidelines and policy
378		responses: a state-of-the-art review. <i>J Hum Hypertens</i> . 2022 Feb:36(32):126-134.
379	12.	2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of
380		the Revision Committee of Chinese Guidelines for Prevention and Treatment of
381		Hypertension. Journal of geriatric cardiology : JGC. 2019;16(3):182-241.
382	13.	Navarro-González D, Sánchez-Íñigo L, Pastrana-Delgado J, Fernández-Montero A,
383		Martinez JA. Triglyceride-glucose index (TyG index) in comparison with fasting
384		plasma glucose improved diabetes prediction in patients with normal fasting glucose:
385		The Vascular-Metabolic CUN cohort. <i>Preventive medicine</i> . 2016;86:99-105.
386	14.	Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, et al. Diagnostic
387		Accuracy of the Triglyceride and Glucose Index for Insulin Resistance: A Systematic
388		Review. International journal of endocrinology. 2020;2020:4678526.
389	15.	Unger G, Benozzi SF, Perruzza F, Pennacchiotti GL. Triglycerides and glucose index:
390		a useful indicator of insulin resistance. Endocrinologia y nutricion : organo de la
391		Sociedad Espanola de Endocrinologia y Nutricion. 2014;61(10):533-540.
392	16.	Soleimani M. Insulin resistance and hypertension: new insights. Kidney international.

## 393 2015;87(3):497-499.

- 394 17. Zheng R, Mao Y. Triglyceride and glucose (TyG) index as a predictor of incident 395 hypertension: a 9-year longitudinal population-based study. Lipids in health and 396 disease. 2017;16(1):175. 397 18. Wang Y, Yang W, Jiang X. Association Between Triglyceride-Glucose Index and 398 Hypertension: A Meta-Analysis. Frontiers in cardiovascular medicine. 2021;8:644035. 399 19. Zhu B, Wang J, Chen K, et al. A high triglyceride glucose index is more closely 400 associated with hypertension than lipid or glycemic parameters in elderly individuals: a 401 cross-sectional survey from the Reaction Study. Cardiovascular diabetology. 402 2020;19(1):112. 403 20. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and 404 Retirement Longitudinal Study (CHARLS). International journal of epidemiology. 405 2014;43(1):61-68 406 21. Wu Z, Zhou D, Liu Y, et al. Association of TyG index and TG/HDL-C ratio with arterial 407 stiffness progression in a non-normotensive population. Cardiovascular diabetology. 408 2021;20(1):134. 409 22. Carbone F, Elia E, Casula M, et al. Baseline hs-CRP predicts hypertension remission 410 in metabolic syndrome. European journal of clinical investigation. 2019;49(8):e13128. 411 23. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of 412 hyperuricemia in the middle-aged and older adults in China. Scientific reports.
- 413 2018;8(1):4314.

414 24. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. BTI - StatPearls.

- 415 25. Li M, Zhan A, Huang X, et al. Positive association between triglyceride glucose index
- 416 and arterial stiffness in hypertensive patients: the China H-type Hypertension Registry
  417 Study. *Cardiovascular diabetology*. 2020;19(1):139.
- 418 26. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
- 419 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
- 420 statement: guidelines for reporting observational studies. *BMJ (Clinical research ed).*
- 421 2007;335(7624):806-808.
- 422 27. Wang K, He G, Zhang Y, et al. Association of triglyceride-glucose index and its
- 423 interaction with obesity on hypertension risk in Chinese: a population-based study.
- 424 *Journal of human hypertension*. 2021;35(3):232-239.
- 425 28. Zhang F, Zhang Y, Guo Z, et al. The association of triglyceride and glucose index, and
- 426 triglyceride to high-density lipoprotein cholesterol ratio with prehypertension and
- 427 hypertension in normoglycemic subjects: A large cross-sectional population study.

428 Journal of clinical hypertension (Greenwich, Conn). 2021;23(7):1405-1412.

- 429 29. Xie Y, Guo R, Li Z, et al. Temporal relationship between body mass index and
- 430 triglyceride-glucose index and its impact on the incident of hypertension. *Nutrition,*

431 *metabolism, and cardiovascular diseases : NMCD.* 2019;29(11):1220-1229.

- Wang F, Han L, Hu D. Fasting insulin, insulin resistance and risk of hypertension in
  the general population: A meta-analysis. *Clinica chimica acta; international journal of*
- 434 *clinical chemistry.* 2017;464:57-63.
- 435 31. Slater EE. Insulin resistance and hypertension. *Hypertension (Dallas, Tex : 1979).*

436 1991;18(3 Suppl):1108-114.

- 437 32. Liu XZ, Fan J, Pan SJ. METS-IR, a novel simple insulin resistance indexes, is
- 438 associated with hypertension in normal-weight Chinese adults. *Journal of clinical*
- 439 *hypertension (Greenwich, Conn).* 2019;21(8):1075-1081.
- 440 33. Minh HV, Tien HA, Sinh CT, et al. Assessment of preferred methods to measure
- insulin resistance in Asian patients with hypertension. *Journal of clinical hypertension*
- 442 *(Greenwich, Conn).* 2021;23(3):529-537.
- 443 34. Fan J, Liu LY, Liu XZ. Hyperinsulinemia negatively affects the association between
- 444 insulin resistance and blood pressure. *Nutrition, metabolism, and cardiovascular*445 *diseases : NMCD.* 2021;31(12):3359-3366.
- 446 35. McGill JB, Haffner S, Rees TJ, Sowers JR, Tershakovec AM, Weber M. Progress and
  447 controversies: treating obesity and insulin resistance in the context of hypertension.

448 *Journal of clinical hypertension (Greenwich, Conn).* 2009;11(1):36-41.

- 449 36. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of
  450 obesity-related hypertension (or, how insulin affects blood pressure, and why). *Journal*
- 451 *of hypertension.* 2001;19(3 Pt 2):523-528.
- 452 37. Takagi M, Tanaka Y, Yamasaki Y, et al. Responsiveness of insulin-induced cardiac

453 sympathetic nerve activation associates with blood pressure regulation in diabetics.

- 454 American journal of physiology Endocrinology and metabolism.
- 455 2003;284(5):E1022-1026.
- 456 38. Fonseca VA. Insulin resistance, diabetes, hypertension, and renin-angiotensin system
  457 inhibition: reducing risk for cardiovascular disease. *Journal of clinical hypertension*458 *(Greenwich, Conn).* 2006;8(10):713-720; guiz 721-712.

- 459 39. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers
- 460 in the metabolic syndrome. *Circulation.* 2004;110(11):1507-1512.
- 461 40. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and
- 462 hypertension: mechanistic links. *Nature reviews Nephrology*. 2019;15(6):367-385.
- 463 41. Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone
- 464 system in hypertension: roles of insulin resistance and oxidative stress. *The Medical*465 *clinics of North America.* 2009;93(3):569-582.
- 466 42. Kaze AD, Musani SK, Correa A, et al. Insulin resistance, metabolic syndrome, and
- 467 blood pressure progression among Blacks: the Jackson Heart Study. *Journal of*
- 468 *hypertension.* 2021;39(11):2200-2209.
- 469 43. Tiano JP, Mauvais-Jarvis F. Importance of oestrogen receptors to preserve functional
- 470 β-cell mass in diabetes. *Nature reviews Endocrinology.* 2012;8(6):342-351.
- 471 44. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and
- 472 energy balance. *Gender medicine.* 2009;6 Suppl 1(Suppl 1):60-75.
- 473 45. Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? *BMC medicine*.
- 474 2014;12:123.
- 475 46. Power ML, Schulkin J. Sex differences in fat storage, fat metabolism, and the health
  476 risks from obesity: possible evolutionary origins. *The British journal of nutrition.*
- 477 2008;99(5):931-940.
- 478 47. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Després JP. Sex differences in
- 479 the relation of visceral adipose tissue accumulation to total body fatness. *The*
- 480 *American journal of clinical nutrition.* 1993;58(4):463-467.

	5	JI 0 J.	1 1 71			
	Stage 1 hypertension	Stage 2 hypertension	ISH	IDH	SDH	
	Adjusted O	R (95% CI)	Adjusted OR (95% CI)			
<b>Overall</b> (N=6,584)						
Quartile 1	Reference	Reference	Reference	Reference	Reference	
Quartile 2	1.10 (0.89-1.35)	1.14 (0.85-1.54)	1.10 (0.88-1.37)	1.50 (0.75-3.00)	1.07 (0.80-1.42)	
Quartile 3	1.26 (1.02-1.55)	1.52 (1.13-2.04)	1.35 (1.08-1.68)	2.04 (1.03-4.04)	1.20 (0.90-1.62)	
Quartile 4	1.71 (1.38-2.13)	1.74 (1.27-2.38)	1.66 (1.31-2.11)	2.52 (1.26-5.05)	1.65 (1.23-2.23)	
TyG-continuous	1.43 (1.27-1.61)	1.42 (1.20-1.67)	1.41 (1.24-1.61)	1.78 (1.30-2.45)	1.35 (1.15-1.58)	
Male (N=3,154)						
Quartile 1	Reference	Reference	Reference	Reference	Reference	
Quartile 2	1.08 (0.81-1.45)	1.05 (0.70-1.58)	1.06 (0.78-1.46)	1.02 (0.41-2.55)	1.11 (0.74-1.64)	
Quartile 3	1.15 (0.85-1.55)	1.24 (0.82-1.88)	1.11 (0.80-1.54)	1.16 (0.47-2.87)	1.34 (0.91-1.99)	
Quartile 4	1.74 (1.28-2.36)	1.33 (0.85-2.09)	1.65 (1.17-2.32)	1.66 (0.68-4.04)	1.62 (1.07-2.44)	
TyG-continuous	1.42 (1.20-1.67)	1.25 (0.98-1.60)	1.36 (1.12-1.65)	1.65 (1.08-2.50)	1.31 (1.06-1.62)	
Female (N=3,430)						
Quartile 1	Reference	Reference	Reference	Reference	Reference	
Quartile 2	1.17 (0.87-1.57)	1.21 (0.79-1.87)	1.22 (0.90-1.67)	3.21 (1.01-10.20)	0.91 (0.58-1.41)	
Quartile 3	1.33 (0.98-1.79)	1.74 (1.14-2.65)	1.47 (1.08-2.01)	4.40 (1.38-14.05)	1.13 (0.73-1.76)	
Quartile 4	1.79 (1.30-2.46)	2.03 (1.30-3.19)	1.81 (1.29-2.54)	3.97 (1.17-13.43)	1.74 (1.11-2.72)	
TyG-continuous	1.44 (1.21-1.71)	1.45 (1.15-1.84)	1.43 (1.19-1.72)	1.73 (1.04-2.87)	1.40 (1.10-1.78)	

Table 1	. Association	of the Ty	G index v	with hyp	pertension star	ges and hy	pertension	phenotypes	s in 2011

Note: TyG, triglyceride-glucose. ISH, isolated systolic hypertension. IDH, isolated diastolic hypertension. SDH, systolic-diastolic hypertension. OR, odds ratio. CI, confidence interval. OR values were adjusted for age, sex, residence, education, economic status, tobacco use, alcohol consumption, general obesity, waist circumstance, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and C-reactive protein.



Maintained Normotension Normotension to Stage 1 Normotension to Stage 2 Maintained Stage 1 Stage 1 to Stage 2 Maintained Stage 2

Maintained Normotension Normotension to Stage 1 Normotension to Stage 2 Maintained Stage 1 Stage 1 to Stage 2 Maintained Stage 2

Maintained Normotension Normotension to Stage 1 Normotension to Stage 2 Maintained Stage 1 Stage 1 to Stage 2 Maintained Stage 2



Odds ratio, 95% confidence interval

- Overall (*N*=4144)
- Male (*N*=1946)
- Female (*N*=2198)



Odds ratio, 95% confidence interval

- Overall (*N*=4126)
- Male (N=1934)
- Female (*N*=2192)